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Abstract
Background In the most cases of oral squamous cell carcinoma (OSCC), oral epithelial dysplasia (OED) is found adjacent 
to the primary tumor. The delineation of surgical margins for OSCC is critical to minimize the risk for local recurrence. The 
aim of this study is to demonstrate that the fluorescence visualization (FV)- device can delineated the lesion visualizes OED 
of adjacent primary tumors by histopathologically comparison to conventional iodine vital staining.
Material and methods The study involved 40 patients with superficial tongue squamous cell carcinoma treated from July 
2016 to July 2018 at the Oral Cancer Center, Tokyo Dental College.
Results Cytokeratin 13 (CK13) expression rate in the area of fluorescence visualization loss (FVL) was significantly lower 
than that in the area of fluorescence visualization retention (FVR). In addition, CK17, Ki-67, and p53 expression rates were 
significantly higher in FVL than FVR. There was no significant difference in the delineation rate or area between FVL and 
iodine-unstained area. High-grade dysplasia was observed most frequently at the FV and iodine-unstained boundary, but no 
significant pathological differences were found.
Conclusion We strongly suggest the FV-guided surgery is a useful method for accurate resection in early-stage tongue 
squamous cell carcinoma.
Keywords Fluorescence visualization · FV-guided surgery · Iodine vital staining · OSCC · Tongue cancer · Surgical 
resection
Introduction
Oral squamous cell carcinoma (OSCC) is the cancer with 
the sixth highest mortality rate worldwide, and the survival 
rate is low. The five-year survival rates for stage 1 tongue 
cancer is 80%, while the five-year survival rates for cancers 
of oral cavities are around 50%. This is largely reflected by 
the fact that many cases are in advanced stages at the time of 
detection. [1] The conventional treatment for early OSCC is 
surgical resection or radiation therapy based on the National 
Comprehensive Cancer Network (NCCN) guidelines [2]. 
Surgical resection is given priority because it is generally 
regarded as effective [3]. Surgeons frequently place the sur-
gical margin at 1.5–2.0 cm from the primary tumor based 
on a visibly abnormal field and palpable area of induration 
according to the NCCN guidelines [2]. However, oral epi-
thelial dysplasia (OED) adjacent to OSCC is difficult to dis-
criminate. Therefore, determination of the surgical margin 
requires more objective evaluation. Most cases of OSCC 
undergo multistep carcinogenesis. Abnormal fields of the 
surgical margin occur due to accumulated genetic changes 
and histological development [4]. Thus, the surgical margin 
is an important therapeutic issue when treating oral cancer 
because a residual abnormal field results in the development 
of a second primary tumor.
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We have identified the abnormal field using conventional 
methods. Toluidine blue and iodine vital staining are repre-
sentative established methods [5]. Surgical resection using 
iodine vital staining is particularly effective for early OSCC 
because it allows for visualization of the boundary of OED 
[6]. Normal non-keratinized epithelium stains well with 
iodine solution; however, abnormal fields with various types 
of dysplasia do not stain well with iodine, exhibiting iodine-
unstained (IUS) areas because of differences in the glycogen 
content of the cytoplasm [7, 8]. Thus, iodine staining allows 
for establishment of the surgical margin of OSCC, leading 
to an improved prognosis [9]. However, iodine vital staining 
has some limitations; for example, the thick oral mucosa of 
keratinizing layers, such as the normal gingival and hard pal-
ate contain low glycogen, and the orthokeratinized epithe-
lium fails to take up iodine [6]. Additionally, iodine some-
times induces adverse reactions [10]. We, therefore, hope 
to develop new approaches as alternatives to iodine vital 
staining that allow for easy management of abnormalities.
The Fluorescence Visualization (FV)- device (VELscope; 
LED Medical Diagnostics, Inc., Vancouver, Canada) is a 
simple hand-held instrument. The FV- device allows for 
direct visualization of the abnormal field by tissue autofluo-
rescence [11–14]. This device uses a blue light in the range 
of 400–460 nm, and a selective filter in the eyepiece allows 
the viewer to directly visualize the pale green color caused 
by the implicated for example collagen matrix or flavin 
adenine dinucleotide [12, 14, 15]. This pale green autofluo-
rescence given off by normal tissue is called FV retention 
(FVR). Conversely, abnormal fields show decreased auto-
fluorescence and appear as dark areas in contrast to the green 
surrounding normal tissue. Such dark areas exhibit FV loss 
(FVL).
The aim of this study is to demonstrate that the FV- 
device can delineated the lesion visualizes OED of adjacent 




This study included 40 patients with early superficial tongue 
squamous cell carcinoma diagnosed pathologically and sur-
gically resected from August 2015 to August 2018 at the 
Oral Cancer Center, Tokyo Dental College. The patients 
consist of 26 men and 14 women with an average age of 
60.0 years (95% confidence interval, 54.3–65.6). In this 
study, we defined early superficial tongue squamous cell 
carcinoma as a tumor of 4 cm in size (T1–T2) with no inva-
sion into the muscle layers and no regional lymph node 
metastasis (N0) (Union for International Cancer Control 7th 
edition). No lesions were detectable by contrast computed 
tomography or magnetic resonance imaging. All patients 
underwent examinations by both FV and iodine vital stain-
ing, and all underwent partial glossectomy. The surgical 
margin was extended an additional 5 mm beyond the lesion 
boundary as guided by the FVL.
This was a prospective study. Written informed consent 
was obtained, and ethical clearance was provided by the 
Ethical Committee of Ichikawa General Hospital, Tokyo 
Dental College, Japan (approval No. I 17-80).
FV‑guided surgery
Observation of tissue autofluorescence was performed with a 
FV device. We resected the tumors with a scalpel in accord-
ance with the FVL and IUS areas in all cases. All procedures 
were performed with the patients under general anesthesia, 
and conditions were standardized as much as possible. Step 
1, initial assessment and measurement under white light 
of early tongue squamous cell carcinoma (Fig. 1-a). Step 
2, perform iodine vital staining by Lugol’s iodine solu-
tion (aqueous iodine solution) was performed and measure 
the dimensions (long and short diameter) of the boundary 
between IUS (Fig. 1-a). Step 3, the FV device was used to 
illuminate the lesions and then mark (with a crystal violet) 
and measure the dimensions (long and short diameter) of 
the boundary between FVL and FVR (Fig. 1-b). Step 4, we 
resected tumor as guided by the FVL based on the guidelines 
established by the Japanese Society of Oral Oncology [16]. 
Step 5, after resection, the FVL boundary was marked with 
a scalpel. Under microscopic observation, the cut mark was 
used as the indicator of the FVL boundary (Fig. 2). IUS area 
considered as PAS negative area.
Evaluation of malignant or premalignant 
biomarkers by immunohistochemistry
Forty specimens were obtained from 40 patients. Immuno-
histochemical staining was performed using an automatic 
immunohistochemistry analyzer (Roche Diagnostics, Basel, 
Switzerland) at room temperature. Sections were cut and 
placed on clean silane-coated glass slides and fixed with 
10% paraformaldehyde. Four mouse monoclonal antibodies 
to cytokeratin 13 (CK13) (× 200 dilution; DE-K13; Dako, 
Glostrup, Denmark), CK17 (× 40 dilution; E3; Dako), Ki-67 
(× 200 dilution; MIB-1; Dako), and p53 (no dilution; Hist-
ofine; Nichirei Corp., Tokyo, Japan) were used to determine 
immunohistochemical expression for FVL and FVR.
The results were analyzed with optical cell counting and 
ImageJ 1.52a cell counter software (National Institutes of 
Health, Bethesda, MD, USA). The labeling index is given 
as an expression rate, and was calculated from the rate of 
CK13- and CK17-positive cells or Ki-67- and p53-positive 
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nuclei. In total, 100–500 epithelial cells were examined in 
every three fields (× 200) [17] (Fig. 3).
Comparison between FV device and iodine vital 
staining method
According to the iodine vital staining method, the IUS area 
is periodic acid-Schiff (PAS)-negative because the glyco-
gen content is absent or lower than that of the normal epi-
thelium [18]. Therefore, the pathological findings can be 
distinguished by the difference in the cytoplasmic glycogen 
content. We performed PAS staining (Muto Pure Chemicals, 
Tokyo, Japan) with an automated slide strainer (Tissue-Tek 
Prisma JOD; Sakura Finetek, Tokyo, Japan). PAS negativity 
indicated an IUS area, therefore, we compared the difference 
between PAS-negative areas and FVL areas.
Expression of PAS‑positive cells in FVL area
We evaluated the glycogen content in keratinized epithelium 
of the FVL area by PAS staining. To examine the PAS-pos-
itive cell distribution and PAS-positive ratio, micrographs 
of each section were taken at a magnification of × 400 for 
every three foci of FVL and FVR. We calculated the labe-
ling index using a previously described method [19]. Lines 
crossing at a right angle to the surface of the basal layer of 
the epithelium were drawn on the micrographs. PAS-positive 
cells touching this line were counted to calculate the number 
of PAS-positive cells. The expression rate of PAS staining 
was calculated as the number of PAS-positive cells divided 
by all cells touching that line [19].
OED in lesion boundary
We compared the pathological findings between the FVL 
and IUS areas at both ends of the lesion boundaries. These 
specimens were observed in every four foci at the bound-
aries. OED was classified according to the World Health 
Organization classification (2017) and divided into low-
grade dysplasia and high-grade dysplasia using a binary 
system [20] (Fig. 3).
Comparison of delineation areas and effective rates 
between FV‑ device and iodine vital staining method
At first, we compared effective rates between the FV device 
and iodine vital staining method. We then measured the lesion 
delineation areas of the FVL and IUS in the same cases. The 
delineated areas were assumed to be the approximate values of 
Fig. 1  Initial assessment and measurement under white light of early 
tongue squamous cell carcinoma. We used to Iodine vital staining 
method for delineation of the iodine-unstained area as borders of dys-
plastic epithelium adjacent to the tongue squamous cell carcinoma 
(a). Assessment of field using FV- device. FVL is outlined in green 
in the dark. Demarcation of FVL boundaries. Schema showing OED 
adjacent to tongue squamous cell carcinoma as fluorescence visuali-
zation loss (FVL). 1. Tumor with FVL. 2, Surgical margin (b)
Fig. 2  Schema showing the cutting point. We set the cutting point at 
the FVL and FVR boundary to prepare the pathological specimen
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the ellipses in the range of the FVL and IUS area. Calculation 
of these areas was performed as follows:
Statistical analysis
The expression rate in immunohistochemical staining and 
pathological findings between the FVL and IUS lesion bound-
ary were analyzed by the Mann–Whitney U test. The differ-
ence in the lesion delineation rate between the iodine vital 
staining method and FV device was statistically analyzed 
by Fisher’s exact test. The correlation between the FVL and 
IUS lesion delineation area were analyzed by Pearson’s prod-
uct–moment correlation. A p value of < 0.01 was considered 
statistically significant. All statistical analyses were performed 
using EZR software (Saitama Medical Center, Jichi Medical 
University, Saitama, Japan).
Ellipse equation = () × (half of long diameter) × (half of short diameter).
Results
Expression of malignant or premalignant 
biomarkers by immunohistochemical staining 
in FVL and FVR boundary
CK13 expression was consistently observed except in the 
basal cell layers. The CK13 expression rate was 91.6% in 
FVR and 41.4% in FVL (p < 0.01) (Fig. 4a).
CK17 expression was observed in the spinous cell 
layer and granular cell layer in FVL. In contrast, CK17 
expression was rarely observed in any layers in FVR. The 
CK17 expression rate was 4.5% in FVR and 49.7% in FVL 
(p < 0.01) (Fig. 4b).
Fig. 3  The labeling index is given as the positive cell ratios, cal-
culated from the percentage of CK17- and CK13-positive cells or 
Ki-67- and p53-positive nuclei. Approximately 100–500 cells were 
examined in each field (× 200). a, b In the fluorescence visualization 
loss (FVL) area, loss of polarity of basal cells and abnormal varia-
tion in nuclear size and shape were observed. Changes were present 
in the upper third of the epithelium. Meanwhile, normal architecture 
and cytology were observed in the fluorescence visualization reten-
tion (FVR) area. c, d CK13 immunoreactivity was observed in the 
upper layers. The FVL showed lower expression of CK13 than the 
FVR. e, f CK17 immunoreactivity was observed in the upper layers 
and part of the lower layers. CK17 expression was rare in FVR com-
pared with FVL. g, h Ki-67 immunoreactivity was observed in the 
basal and parabasal cell layers. Higher expression of Ki-67 was found 
in FVL than FVR. i, j p53 immunoreactivity was also observed in the 
basal and parabasal cell layers. Higher expression of p53 was found 
in FVL than FVR
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Ki-67 expression was scattered throughout the basal and 
spinous cell layers. The Ki-67 expression rate was 27.3% 
in FVR and 40.9% in FVL (p < 0.01) (Fig. 4c). The expres-
sion of p53 was chiefly found in cells of the basal layer 
and the lower or middle part of the spinous cell layer. The 
expression rate of p53 was 11.2% in FVR and 26.8% in FVL 
(p < 0.01) (Fig. 4d). The distribution patterns of Ki-67- and 
p53-positive cells in the FVL area were extremely similar, 
and reactive cells were found in not only the basal, but also 
the spinous cell layers.
Comparison between FV device and iodine vital 
staining method
PAS-negative cells were observed in all layers of the epithe-
lium in FVL. In contrast, PAS-positive cells were observed 
in only the spinous, granular, and keratinized layers in 
FVR. The expression rate of PAS staining was 59.5% in 
FVL and 64.9% in FVR (p < 0.01) (Fig. 4e). The FVL and 
IUS boundary were similar in many cases despite different 
mechanisms.
At the lesion boundaries, high-grade dysplasia was 
observed in 63.8% of cases at the FVL and in 69.4% of the 
IUS area. Low-grade dysplasia was observed in 36.3% of 
the FVL and in 30.6% of the IUS area. There were no sig-
nificant histopathological differences between the FVL and 
IUS boundary (p = 0.34) (Fig. 5).
The effective rates for the FV device was 100% (40 cases). 
However, that for the iodine vital staining method was 72.5% 
(29 cases). The reason for the imperfection of iodine vital 
staining is that 9 of 11 cases could not be delineated, and 
the other 2 cases could not be examined because of iodine 
hypersensitivity. The lesion delineation rate was signifi-
cantly higher with the FV device than iodine vital staining 
method (p < 0.01). However, the median lesion delineation 
area was 113.3  mm2 in FVL and 81.5  mm2 in the IUS area 
(p = 0.13) (Fig. 6a). The FVL and IUS areas demonstrated a 
strong correlation (r = 0.752, p < 0.01) (Fig. 6b).
Fig. 4  Expression rates of CK13, CK17, Ki67, p53, and PAS stain-
ing. The horizontal center line in each box indicates the median, and 
the vertical line indicates the expression rate. The upper edge of each 
box shows the third quartile deviation, and the lower edge shows the 
first quartile deviation
Fig. 5  Description of lesion boundary. Various types of OED were 
observed at the lesion boundary between the area of fluorescence 
visualization loss (mild, 11.9%; moderate, 24.4%; severe, 63.8%) and 
iodine-unstained area (mild, 8.6%; moderate, 21.9%; severe, 69.4%). 
We classified high-grade dysplasia and low-grade dysplasia and 
found no significant differences (p = 0.34)
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Discussion
The concept of “field cancerization” was introduced by 
Slaughter et al. [21] in 1953. The “field” refers to the abnor-
mal tissue adjacent to the tumor, which develops in a mul-
tistep process of carcinogenesis. Furthermore, many recent 
studies have confirmed that this field has a high potential for 
malignant transformation with several types of oral epithe-
lial dysplasia [4]. Morphologically, oral epithelial dysplasia 
develops into malignancy in 12.0–15.4% of cases [22, 23]. 
Additionally, some reports have stated that local recurrence 
occurs in 5.6–19.0% of T1–T2 early-stage OSCC [24–26]. 
Visualization of such an abnormal field with iodine vital 
staining was chosen because of its low cost, wide availabil-
ity, and ease of use. McMahon et al. [6] reported that the 
use of Lugol’s iodine could reduce the incidence of dys-
plasia at the surgical margins in the resection of oral and 
oropharyngeal carcinoma. This direct FV method was more 
recently considered to have potential as a simple, noninva-
sive, repeatable screening device for early detection of oral 
premalignant lesions.
The purpose of this study was to prove that the FVL 
area is precancerous area histopathologically. Moll et al. 
[27] reported that several types of cytokeratin have great 
importance in immunohistochemical tumor diagnosis of car-
cinomas. CK13 is expressed in normal epithelium, and its 
expression tends to decrease in high-grade dysplasia [28]. 
Additionally, CK17 expression was higher in squamous cell 
carcinoma and lower in low-grade dysplasia and normal epi-
thelium [29]. The expression of these cytokeratins indicates 
that they are accurate premalignant markers for evaluation 
of the abnormal field with malignant potential [17, 19, 30, 
31]. In the present study, CK13 expression was significantly 
lower and CK17 expression was significantly higher at the 
FVL boundary than at the FVR. Thus, we found that the 
FVL area clinically reflects the concept of an abnormal field 
with malignant potential.
Ki-67 is a representative molecular marker of proliferat-
ing cells, and its labeling index correlates with the degree of 
high-grade dysplasia and severity of malignancy. Ohta et al. 
[32] reported that CK13 and Ki-67 expression was signifi-
cantly different between iodine-stained and -unstained areas 
and that an abnormal field showing precancerous or cancer-
ous features was detected at the IUS boundary. Moreover, 
p53 is a well-known tumor suppressor gene that introduces 
G1 arrest to allow the repair of DNA damage. Many studies 
have shown that p53 mutation occurs in the initial step of 
cancerization [17, 19, 33]. One study showed that the p53 
expression rate was higher in oral epithelial dysplasia with 
high malignant potential than in carcinoma in situ or early-
stage OSCC [34]. Taken together, these findings indicate 
that expression of Ki-67 and p53 in early-stage OSCC are 
important as initial signs of carcinogenesis [17, 19, 32, 33].
In the present study, we found that both Ki-67 and p53 
were more highly expressed within abnormal fields under 
FV-guided surgery. Field cancerization based on the molecu-
lar abnormalities has shown that the presence of allelic loss 
at 3p, 9p, and 17p is associated with an increased cancer 
risk [4, 11]. A previous study showed an important step in 
the loss of heterozygosity analysis on each FVL boundary 
and a significant association of loss of heterozygosity at 3p 
and/or 9p based on mutations in TP53 [11]. These results 
Fig. 6  a Comparison of lesion delineation area. b Pearson’s prod-
uct–moment correlation. 11 patients were excluded because the 
iodine-unstained (IUS) area did not appear in the iodine vital staining 
method. The data indicated a strong correlation between the fluores-
cence visualization loss (FVL) delineation area and the IUS delinea-
tion area (p < 0.01, 95% confidence interval = 0.532–0.877)
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may suggest that the FV device can delineate between the 
primary tumor and oral epithelial dysplasia with malignant 
potential based on field cancerization. Removal of the delin-
eating area under FV-guided surgery may reduce the risk of 
a poor prognosis because of development a second primary 
tumor.
The present study also raises an important issue regard-
ing the relative advantages of the iodine staining method 
and FV-guided surgery. The areas of normal epithelial tis-
sue were PAS-positive because parakeratotic epithelial tis-
sue contains a large amount of glycogen [18]. The PAS-
negative area is well known to be equivalent to the IUS 
area [18]; likewise, most of the IUS area is correlated with 
high-grade dysplasia. In the present study, we found that all 
IUS areas consisted of oral epithelial dysplasia. Thus, the 
IUS areas that appeared in the 29 patients who underwent 
the performed iodine staining method were included in the 
resected specimens. Moreover, the FVL area was similar to 
the IUS area. The FVL boundary showed low- or high-grade 
dysplasia.
Several studies have shown that the pathological findings 
between the IUS and FVL areas might similarly consist of 
various types of dysplasia [35, 36]. However, the abnormal 
fields delineated by the FV- device are obviously obtained 
by different mechanisms than in the iodine vital staining 
method. For this reason, the FVL area was not always visu-
ally identical to the IUS area. The results of this study sug-
gest that the FV- device is superior to the iodine staining 
method in aiding in the identification of the boundary of 
OED associated with OSCC prior to surgical resection. As 
described above, we recommend using not only iodine vital 
staining but also FV for detection of the surgical margin. The 
effective rate in iodine vital staining was about 70–80% [5, 7, 
8, 35], although there is a difference depending on the iodine 
concentration. In this study, the results were almost the 
same. However, the iodine vital staining method exhibited 
imperfect delineating ability in nine cases and could not be 
performed because of iodine hypersensitivity in two cases. 
These two patients underwent only FV-guided surgery. FV-
guided surgery may compensate for the shortcomings of the 
iodine vital staining method. Furthermore, the iodine vital 
staining method sometimes induced allergic reactions.
One of the limitations of complicated resection with 
iodine vital staining and FV is that only superficial lesions 
can be detected [11]. Advanced OSCC with deep invasion 
would cause no fluorescence alterations. However, the 
advantage of this device lies in the detection of early-stage 
and superficial of OSCC in clinically suspected cases that 
cannot be completely visualized by the naked eye. We hope 
that educational activities on early detection will be imple-
mented to engage the medical community in the field of oral 
oncology and that the prognosis will be improved through 
further studies of FV-guided surgery. Accurate detection and 
differentiation of early-stage OSCC can have a significant 
effect on increasing the rate of early diagnosis. FV may be 
a beneficial tool in the evaluation of mucosal lesions when 
the situational context is taken into account. Our results 
showed a significant difference between normal and abnor-
mal mucosa. In addition, analysis software that digitizes and 
graphs the difference in brightness between FVL and FVR 
is also being developed, and we believe that more accurate 
objective evaluation will be possible in the future, currently. 
The FV device appears to be a useful noninvasive aid in the 
management of potentially malignant lesions. In conclusion, 
we strongly suggest the performance of FV-guided surgery 
for accurate resection of primary tumors, including OED 
with malignant potential.
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